Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DVC1 0101

Drug Profile

DVC1 0101

Alternative Names: Angiogenic-gene-therapy-ID-Pharma; BF-30; DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; Recombinant SeV-hFGF2/dF; SeV-10101; SeV-hFGF2/dF; SEV1-0101

Latest Information Update: 20 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University; Shenzhen Salubris Pharmaceuticals
  • Class Anti-ischaemics; Gene therapies; Nucleic acids; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intermittent claudication; Peripheral ischaemia
  • Phase I Peripheral arterial occlusive disorders

Most Recent Events

  • 05 Sep 2018 Phase-I clinical trials in Peripheral arterial occlusive disorders in China (IM) (NCT03668353)
  • 22 Nov 2016 Phase-I/II clinical trials in Intermittent claudication in Australia (IM) (ACTRN12615001144505)
  • 22 Nov 2016 Phase-I/II clinical trials in Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top